These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37837490)

  • 1. Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial.
    Wu Y; Zhou X; Zhao W; Wang Q; Han Z; Wang L; Zhou W; Zhou T; Song H; Chen Y; Yang K; Shi L; Pan B; Guo R; Zhou G; Jiang F; Feng J; Shen B
    Invest New Drugs; 2023 Dec; 41(6):825-833. PubMed ID: 37837490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
    Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
    Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.
    Liu C; Liao J; Wu X; Zhao X; Sun S; Wang H; Hu Z; Zhang Y; Yu H; Wang J
    Thorac Cancer; 2022 May; 13(10):1463-1470. PubMed ID: 35388976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial.
    Deng P; Hu C; Chen C; Cao L; Gu Q; An J; Qin L; Li M; He B; Jiang J; Yang H
    Cancer Med; 2022 Oct; 11(19):3563-3571. PubMed ID: 35526266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2).
    Zhang W; Deng P; Kong T; Zhang B; Qian F; Dong Y; Chen Y; Chen L; Liu D; Zhang Y; Yang H; Han B
    Lung Cancer; 2022 Nov; 173():43-48. PubMed ID: 36116169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of anlotinib plus anti-programmed cell death 1/ligand 1 (anti-PD-1/PD-L1) antibodies as maintenance therapy after first-line chemotherapy combined with anti-PD-1/PD-L1 antibodies in extensive-stage small cell lung cancer: a real-world study.
    Yang P; Luo H; Zhao L; Xiong F; Tang C
    J Thorac Dis; 2024 Jul; 16(7):4391-4399. PubMed ID: 39144292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study.
    Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Ruan ZP; Tian T; Liang X; Yao Y
    Front Oncol; 2022; 12():894835. PubMed ID: 36203439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
    Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
    Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study.
    Li Y; Sun Z; Sun W; Wang H; Zu J
    Clin Med Insights Oncol; 2022; 16():11795549211067184. PubMed ID: 35095286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study.
    Lv XM; Liu Y; Feng Y; Liang HL; Zhi WW
    J Cancer; 2024; 15(11):3539-3546. PubMed ID: 38817880
    [No Abstract]   [Full Text] [Related]  

  • 11. Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial.
    He Z; Zhou H; Wang J; Li D; Zhang X; Wang P; Ma T; Zhang Y; Tian C; Chen Y; Zou M; Han Y; Xu C; Ma S; Wang L; Wu X; Chen G; Wang Q
    Transl Lung Cancer Res; 2021 Feb; 10(2):889-899. PubMed ID: 33718030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
    Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
    Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
    Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
    Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in
    He Z; Yang X; Ma T; Yang Q; Zhang C; Chen Y; Wang P; D'Incecco A; Metro G; Uematsu S; Wang Q
    Transl Lung Cancer Res; 2022 Aug; 11(8):1657-1666. PubMed ID: 36090635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
    Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of anlotinib as maintenance therapy after induction chemotherapy in extensive-stage small-cell lung cancer.
    Wang N; Zhao L; Zhang D; Kong F
    Anticancer Drugs; 2023 Apr; 34(4):558-562. PubMed ID: 36728981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.
    Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Zhang R; Ruan ZP; Tian T; Liang X; Yao Y
    Cancer Manag Res; 2022; 14():2273-2287. PubMed ID: 35942069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study).
    Li D; Huang Z; Zhong J; Lin L; Zhang G; Zhuang W; Liu Z
    BMC Cancer; 2023 Aug; 23(1):753. PubMed ID: 37580661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.